# Immunopeptidome

Source: https://onco.cc/terms/immunopeptidome/  
OnCo record `immunopeptidome` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The immunopeptidome is the collection of peptides associated with immune display molecules in a particular biological setting. A measurement recovers a view of that collection through a defined assay.

## Summary

An immunopeptidome concerns displayed peptide ligands, rather than every protein or RNA message in a sample. Direct analysis of native melanoma tissue identified HLA-associated peptides, including some containing tumor mutations. What is recovered depends on the tissue and analytical workflow. The observed collection should retain its sample and method, and identifying a displayed peptide remains distinct from showing an immune response to it.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: HLA ligandome; HLA peptidome

## Notes

- The immunopeptidome is a biological repertoire in a defined cell population and context; an immunopeptidomics list is a method-dependent subset recovered and identified from a sample. Class I and class II repertoires are separate, and a protein can be abundant while a derived peptide is poorly generated, loaded or retained. Inflammatory signals changed peptide patterns in cancer cell lines (Chong et al., 2018, ovarian cancer cells and interferon gamma, PMID 29242379; Javitt et al., 2019, lung cancer cells and TNF-alpha and interferon gamma acting through HLA-B, PMID 30833945), which shows context-dependent remodelling and not that inflammation adds useful targets. Whole-lysate capture can recover intracellular as well as surface complexes, mixed tissue adds cancer, immune and stromal sources, relative instrument intensity is not surface copies per cell, and a reported sequence can be misassigned (Wilhelm et al., 2021, PMID 34099720). Method B identifying 1,200 peptides against method A's 800 (fictional) shows no biological difference. Sarkizova et al. (2020) gives allele-dependent repertoires from mono-allelic lines.

## Sources

- Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.: https://doi.org/10.1038/ncomms13404
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1074/mcp.tir117.000383
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.3389/fimmu.2019.00141
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1038/s41467-021-23713-9
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1038/s41587-019-0322-9
- Primary evidence for the antigen-presentation teaching distinctions: https://doi.org/10.1038/s41596-019-0133-y

## Connected records

- terms: [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Immunopeptidomics](https://onco.cc/terms/immunopeptidomics/), [Peptide binding, presentation and immune recognition](https://onco.cc/terms/binding-presentation-recognition/)
- technologies: [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/)

---
JSON: https://onco.cc/api/v1/entities/immunopeptidome.json